Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. 2014

Bohuslav Melichar, and Hana Študentova, and Hana Kalábová, and Denisa Vitásková, and Petra Čermáková, and Helena Hornychová, and Aleš Ryška
Professor and Head, Department of Oncology, Palacký University Medical School & Teaching Hospital, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic. bohuslav.melichar@fnol.cz.

Despite the progress of tailored therapeutic strategies in patients with breast cancer, there is an unmet medical need for additional biomarkers that would guide therapy, including the administration of targeted agents. It has been demonstrated that the presence of tumor-infiltrating lymphocytes (TILs) is associated with prognosis in patients with early breast cancer. Moreover, TIL counts were shown to predict outcome of neoadjuvant chemotherapy. The neoadjuvant setting is increasingly used to assess the efficacy of new systemic therapies, and TILs are promising as a biomarker reflecting the immune response to tumor. Future studies should investigate on the integration of TILs as predictive biomarkers in patients treated with targeted- agents.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016246 Lymphocytes, Tumor-Infiltrating Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer. Tumor Infiltrating Lymphocyte,Tumor-Derived Activated Cell,Tumor-Derived Activated Cells,Tumor-Infiltrating Lymphocyte,Tumor-Infiltrating Lymphocytes,Activated Cell, Tumor-Derived,Activated Cells, Tumor-Derived,Infiltrating Lymphocyte, Tumor,Infiltrating Lymphocytes, Tumor,Lymphocyte, Tumor Infiltrating,Lymphocyte, Tumor-Infiltrating,Lymphocytes, Tumor Infiltrating,Tumor Derived Activated Cell,Tumor Derived Activated Cells,Tumor Infiltrating Lymphocytes
D020360 Neoadjuvant Therapy Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy. Neoadjuvant Chemoradiation,Neoadjuvant Chemoradiation Therapy,Neoadjuvant Chemoradiation Treatment,Neoadjuvant Chemoradiotherapy,Neoadjuvant Chemotherapy,Neoadjuvant Chemotherapy Treatment,Neoadjuvant Radiation,Neoadjuvant Radiation Therapy,Neoadjuvant Radiation Treatment,Neoadjuvant Radiotherapy,Neoadjuvant Systemic Therapy,Neoadjuvant Systemic Treatment,Neoadjuvant Treatment,Chemoradiation Therapy, Neoadjuvant,Chemoradiation Treatment, Neoadjuvant,Chemoradiation, Neoadjuvant,Chemoradiotherapy, Neoadjuvant,Chemotherapy Treatment, Neoadjuvant,Chemotherapy, Neoadjuvant,Neoadjuvant Chemoradiation Therapies,Neoadjuvant Chemoradiation Treatments,Neoadjuvant Chemoradiations,Neoadjuvant Chemoradiotherapies,Neoadjuvant Chemotherapies,Neoadjuvant Chemotherapy Treatments,Neoadjuvant Radiation Therapies,Neoadjuvant Radiation Treatments,Neoadjuvant Radiations,Neoadjuvant Radiotherapies,Neoadjuvant Systemic Therapies,Neoadjuvant Systemic Treatments,Neoadjuvant Therapies,Neoadjuvant Treatments,Radiation Therapy, Neoadjuvant,Radiation Treatment, Neoadjuvant,Radiation, Neoadjuvant,Radiotherapy, Neoadjuvant,Systemic Therapy, Neoadjuvant,Systemic Treatment, Neoadjuvant,Therapy, Neoadjuvant,Therapy, Neoadjuvant Chemoradiation,Therapy, Neoadjuvant Radiation,Therapy, Neoadjuvant Systemic,Treatment, Neoadjuvant,Treatment, Neoadjuvant Chemoradiation,Treatment, Neoadjuvant Chemotherapy,Treatment, Neoadjuvant Radiation,Treatment, Neoadjuvant Systemic

Related Publications

Bohuslav Melichar, and Hana Študentova, and Hana Kalábová, and Denisa Vitásková, and Petra Čermáková, and Helena Hornychová, and Aleš Ryška
May 2023, World journal of surgery,
Bohuslav Melichar, and Hana Študentova, and Hana Kalábová, and Denisa Vitásková, and Petra Čermáková, and Helena Hornychová, and Aleš Ryška
December 2016, Clinical cancer research : an official journal of the American Association for Cancer Research,
Bohuslav Melichar, and Hana Študentova, and Hana Kalábová, and Denisa Vitásková, and Petra Čermáková, and Helena Hornychová, and Aleš Ryška
July 2017, Oncology letters,
Bohuslav Melichar, and Hana Študentova, and Hana Kalábová, and Denisa Vitásková, and Petra Čermáková, and Helena Hornychová, and Aleš Ryška
December 2023, Cancer research communications,
Bohuslav Melichar, and Hana Študentova, and Hana Kalábová, and Denisa Vitásková, and Petra Čermáková, and Helena Hornychová, and Aleš Ryška
January 2021, American journal of translational research,
Bohuslav Melichar, and Hana Študentova, and Hana Kalábová, and Denisa Vitásková, and Petra Čermáková, and Helena Hornychová, and Aleš Ryška
October 2017, Pancreas,
Bohuslav Melichar, and Hana Študentova, and Hana Kalábová, and Denisa Vitásková, and Petra Čermáková, and Helena Hornychová, and Aleš Ryška
January 2017, Ecancermedicalscience,
Bohuslav Melichar, and Hana Študentova, and Hana Kalábová, and Denisa Vitásková, and Petra Čermáková, and Helena Hornychová, and Aleš Ryška
December 2022, Breast (Edinburgh, Scotland),
Bohuslav Melichar, and Hana Študentova, and Hana Kalábová, and Denisa Vitásková, and Petra Čermáková, and Helena Hornychová, and Aleš Ryška
March 2024, Biomedicines,
Bohuslav Melichar, and Hana Študentova, and Hana Kalábová, and Denisa Vitásková, and Petra Čermáková, and Helena Hornychová, and Aleš Ryška
February 2024, Medicine,
Copied contents to your clipboard!